首頁 > 市場調查報告書 > 製藥

癌症

北美膠質瘤治療市場預測至 2030 年 - 區域分析 - 按疾病、治療類型、等級和最終用戶

市場調查報告書

商品編碼

1452589

北美膠質瘤治療市場預測至 2030 年 - 區域分析 - 按疾病、治療類型、等級和最終用戶

North America Glioma Treatment Market Forecast to 2030 - Regional Analysis - by Disease, Treatment Type, Grade, and End User

出版日期: 2024年01月15日 | 出版商:

The Insight Partners | 英文 92 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

北美膠質瘤治療市場預計將從2022年的21.7988億美元成長到2030年的43.7738億美元。預計2022年至2030年CAGR為9.1%。

地區和州政府為患者提供治療機會的舉措推動了北美神經膠質瘤治療市場

2021 年 12 月，患者訪問網路 (PAN) 基金會和美國腦腫瘤協會宣佈建立新的合作夥伴關係，透過為患者提供每年高達 1,600 美元的服務財政援助來支持膠質母細胞瘤患者。此外，北美神經膠質瘤治療市場的領先公司專注於推出新產品和開發現有產品。 2020年12月，CNS Pharmaceuticals, Inc.宣布美國食品藥物管理局授權使用貝柔比星治療多形性膠質母細胞瘤患者。此外，美國食品藥物管理局於 2021 年 8 月將 Lantern Pharma Inc. 的 LP-184 指定為孤兒藥，用於治療多形性膠質母細胞瘤和其他惡性膠質瘤。 2020 年5 月還舉辦了一場關於多形性膠質母細胞瘤(GBM) 以及Lantern Pharma 的LP-184 治療GBM 和其他類型腦癌的潛力的網路研討會。因此，區域和州政府努力為患者提供獲取途徑新療法加速了北美神經膠質瘤治療市場的成長。

北美神經膠質瘤治療市場概述

北美的神經膠質瘤治療市場分為美國、加拿大和墨西哥；美國在該地區佔有最大的市場佔有率。市場成長主要歸因於腦腫瘤病例的增加、技術的快速創新和醫療基礎設施的發展。根據美國腦瘤協會 2023 年發布的報告，膠質母細胞瘤是最致命、最複雜且難以治療的癌症之一。預計到 2023 年，將有超過 14,490 名美國人被診斷為 GBM，約佔所有原發性惡性腦瘤的 50.1%。北美市場的知名企業正在專注於各種成長策略，例如合併、收購、合作夥伴關係和新產品發布，以擴大其地理影響力並增強其產品供應。例如，總部位於瑞典的 Elekta 公司與 GE Healthcare 合作，在放射腫瘤學領域帶來創新。透過此次合作，醫院將為需要放射治療的癌症患者提供廣泛的治療。

美國在北美神經膠質瘤治療市場中佔有重要佔有率。這個國家的市場成長主要是由腦腫瘤盛行率的增加、神經膠質瘤治療技術的不斷進步以及吸菸者數量的增加所推動的。根據美國臨床腫瘤學會 (ASCO) 的數據，預計到 2022 年，美國將有近 24,530 名成年人（13,840 名男性和 10,690 名女性）被診斷出患有原發性腦部和脊髓癌性腫瘤。腦腫瘤是原發性中樞神經系統（CNS）惡性腫瘤，佔所有原發性中樞神經系統病例的85-90%。隨著腦腫瘤病例數量的增加，對更快治療的需求也在增加。根據加拿大腦瘤登記處的數據，加拿大每 10 萬人中就有 4 人患有膠質母細胞瘤，每年有近 1,000 名加拿大人被診斷出患有膠質母細胞瘤。膠質母細胞瘤治療市場參與者正在採用各種有機和無機策略來在加拿大市場取得成功。 2021 年 2 月，Medexus Pharmaceuticals Inc. 啟動了 Gleolan 在加拿大的商業上市，此前該藥物僅根據加拿大衛生部特別准入計劃進行分銷。 Gleolan 是一種顯影劑，可導致高級神經膠質瘤（惡性且快速進展的腦腫瘤）在藍光下發出螢光，幫助神經外科醫生更好地觀察這些神經膠質瘤，以便完全切除。目前加拿大沒有其他核准的光學影像劑可用於在神經膠質瘤手術期間可視化惡性組織。此外，發展醫療基礎設施、增加研發投資以及治療程序的改進預計將在預測期內推動墨西哥的北美神經膠質瘤治療市場。

北美膠質瘤治療市場收入及 2030 年預測（百萬美元）

北美膠質瘤治療市場細分

北美神經膠質瘤治療市場按疾病、治療類型、等級、最終用戶和國家細分。

根據疾病，北美神經膠質瘤治療市場分為星狀細胞瘤、少突星狀細胞瘤和少突膠質細胞瘤。 2022 年，星狀細胞瘤細分市場佔據北美神經膠質瘤治療市場的最大佔有率。

依治療類型，北美神經膠質瘤治療市場分為手術、化療、放射治療等。 2022年，手術細分市場佔據北美神經膠質瘤治療市場的最大佔有率。

根據級別，北美神經膠質瘤治療市場分為低級別和高級別。 2022 年，高層級細分市場在北美神經膠質瘤治療市場中佔有更大佔有率。

根據最終用戶，北美神經膠質瘤治療市場分為醫院和診所以及門診手術中心。 2022 年，醫院和診所部門在北美神經膠質瘤治療市場中佔有更大佔有率。

依國家/地區分類，北美神經膠質瘤治療市場分為德國、美國、加拿大和墨西哥。 2022年，美國主導北美神經膠質瘤治療市場。

Amgen Inc、Amneal Pharmaceuticals Inc、Arbor Pharmaceuticals LLC、Biocon Ltd、F. Hoffmann-La Roche Ltd、Karyopharm Therapeutics Inc、Merck & Co Inc、Pfizer Inc、Sun Pharmaceutical Industries Ltd 和 Teva Pharmaceutical Industries Ltd 是一些領先公司經營北美神經神經系統膠質瘤治療市場。

In December 2021, the Patient Access Network (PAN) Foundation and the American Brain Tumor Association announced a new partnership to support persons with glioblastoma by offering financial assistance for services worth up to US$ 1,600 per year for patients. Moreover, leading companies in the North America glioma treatment market focus on launching new products and developing existing ones. In December 2020, CNS Pharmaceuticals, Inc. announced the authorization of the use of berubicin by the Food and Medication Administration to treat patients with glioblastoma multiforme. In addition, the Food and Medication Administration designated LP-184 by Lantern Pharma Inc. as an orphan medication in August 2021 for treating glioblastoma multiforme and other malignant gliomas. A webinar on glioblastoma multiforme (GBM) and the potential of Lantern Pharma\'s LP-184 for treating GBM and other types of brain cancer was also held in May 2020. Thus, efforts made by regional and state governments to provide patients with access to novel treatments accelerate the North America glioma treatment market growth.

North America Glioma Treatment Market Overview

The North America glioma treatment market in North America is segmented into the US, Canada, and Mexico; the US holds the largest share of the market in this region. The market growth is mainly attributed to the increasing brain tumor cases, rapid technological innovations, and developing healthcare infrastructure. According to a report published by the National Brain Tumor Society in 2023, glioblastoma is one of the deadliest, most complex, and treatment-resistant forms of cancer. Over 14,490 Americans are projected to receive a GBM diagnosis in 2023, accounting for ~50.1% of all primary malignant brain tumors. Prominent players in the North American market are focusing on various growth strategies such as mergers, acquisitions, partnerships, and new product launches to expand their geographic presence and enhance their product offerings. For instance, Elekta, a Sweden-based company, collaborated with GE Healthcare to bring innovations in the field of radiation oncology. Through this collaboration, hospitals would be provided with a wide range of treatments for cancer patients requiring radiation therapy.

The US holds a significant share of the North America glioma treatment market in North America. The market growth in this country is primarily driven by the increasing prevalence of brain tumor, growing technological advancements in glioma treatment, and the rising number of smokers. According to the American Society of Clinical Oncology (ASCO), in 2022, nearly 24,530 adults (13,840 men and 10,690 women) are estimated to be diagnosed with primary cancerous tumors of the brain and spinal cord in the US. Brain tumors are the primary central nervous system (CNS) malignancies, which account for 85-90% of all primary CNS cases. The demand for faster treatment is growing with the rising number of brain tumor cases. According to the Brain Tumor Registry of Canada, 4 out of 100,000 people in Canada suffer from glioblastoma, and nearly 1,000 Canadians are diagnosed with glioblastoma each year. The glioblastoma treatment market players are adopting various organic and inorganic strategies to succeed in the Canadian market. In February 2021, Medexus Pharmaceuticals Inc. initiated the commercial launch of Gleolan in Canada, which was previously only distributed under the Health Canada special access program. Gleolan is an imaging agent that causes high-grade gliomas (malignant and rapidly progressing brain tumors) to fluoresce under blue light, helping neurosurgeons better visualize these gliomas for complete removal. There are currently no other approved optical imaging agents in Canada for visualizing malignant tissues during glioma surgery. Further, developing healthcare infrastructure, increasing investments in research & development, and improvements in treatment procedures are anticipated to drive the North America glioma treatment market in Mexico during the forecast period.

North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Million)

North America Glioma Treatment Market Segmentation

The North America glioma treatment market is segmented into disease, treatment type, grade, end user, and country.

Based on disease, the North America glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held the largest share of the North America glioma treatment market in 2022.

Based on treatment type, the North America glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held the largest share of the North America glioma treatment market in 2022.

Based on grade, the North America glioma treatment market is segmented into low grade and high grade. The high grade segment held a larger share of the North America glioma treatment market in 2022.

Based on end user, the North America glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held a larger share of the North America glioma treatment market in 2022.

Based on country, the North America glioma treatment market is segmented into Germany, the US, Canada, and Mexico. The US dominated the North America glioma treatment market in 2022.

Amgen Inc, Amneal Pharmaceuticals Inc, Arbor Pharmaceuticals LLC, Biocon Ltd, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the North America glioma treatment market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Glioma Treatment Market - Key Industry Dynamics

4.1 Market Drivers
- 4.1.1 Initiatives by Regional and State Governments to Provide Patients Access to Treatment
- 4.1.2 Increase in Prevalence of High-Grade Glioma
4.2 Key Market Restraints
- 4.2.1 High Cost of Diagnosis
4.3 Key Market Opportunities
- 4.3.1 Advancements in Healthcare Sector
4.4 Future Trends
- 4.4.1 Surge in Drug Approvals for Glioma Treatment
4.5 Impact Analysis:

5. Glioma Treatment Market - North America Market Analysis

5.1 North America Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030

6. North America Glioma Treatment Market - Revenue and Forecast to 2030 - by Disease

6.1 Overview
6.2 North America Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
6.3 Astrocytoma
- 6.3.1 Overview
- 6.3.2 Astrocytoma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Oligoastrocytoma
- 6.4.1 Overview
- 6.4.2 Oligoastrocytoma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Oligodendroglioma
- 6.5.1 Overview
- 6.5.2 Oligodendroglioma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Glioma Treatment Market - Revenue and Forecast to 2030 - by Treatment Type

7.1 Overview
7.2 North America Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
7.3 Surgery
- 7.3.1 Overview
- 7.3.2 Surgery: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Chemotherapy
- 7.4.1 Overview
- 7.4.2 Chemotherapy: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Radiation Therapy
- 7.5.1 Overview
- 7.5.2 Radiation Therapy: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Glioma Treatment Market - Revenue and Forecast to 2030 - by Grade

8.1 Overview
8.2 North America Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
8.3 Low Grade
- 8.3.1 Overview
- 8.3.2 Low Grade: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.1 Grade I: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.2 Grade II: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
8.4 High Grade
- 8.4.1 Overview
- 8.4.2 High Grade: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.1 Grade III: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.2 Grade IV: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Glioma Treatment Market - Revenue and Forecast to 2030 - by End User

9.1 Overview
9.2 North America Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Hospital & Clinics
- 9.3.1 Overview
- 9.3.2 Hospital & Clinics: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Ambulatory Surgical Centers
- 9.4.1 Overview
- 9.4.2 Ambulatory Surgical Centers: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Glioma Treatment Market - Country Analysis

10.1 Overview
- 10.1.1 North America Glioma Treatment Market, by Country
  - 10.1.1.1 US
    - 10.1.1.1.1 US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.1.2 US: North America Glioma Treatment Market, by Disease
    - 10.1.1.1.3 US: North America Glioma Treatment Market, by Treatment Type
    - 10.1.1.1.4 US: North America Glioma Treatment Market, by Grade
    - 10.1.1.1.4.1 US: North America Glioma Treatment Market, by Low Grade
    - 10.1.1.1.4.2 US: North America Glioma Treatment Market, by High Grade
    - 10.1.1.1.5 US: North America Glioma Treatment Market, by End User
  - 10.1.1.2 Canada
    - 10.1.1.2.1 Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.2.2 Canada: North America Glioma Treatment Market, by Disease
    - 10.1.1.2.3 Canada: North America Glioma Treatment Market, by Treatment Type
    - 10.1.1.2.4 Canada: North America Glioma Treatment Market, by Grade
    - 10.1.1.2.4.1 Canada: North America Glioma Treatment Market, by Low Grade
    - 10.1.1.2.4.2 Canada: North America Glioma Treatment Market, by High Grade
    - 10.1.1.2.5 Canada: North America Glioma Treatment Market, by End User
  - 10.1.1.3 Mexico
    - 10.1.1.3.1 Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.3.2 Mexico: North America Glioma Treatment Market, by Disease
    - 10.1.1.3.3 Mexico: North America Glioma Treatment Market, by Treatment Type
    - 10.1.1.3.4 Mexico: North America Glioma Treatment Market, by Grade
    - 10.1.1.3.4.1 Mexico: North America Glioma Treatment Market, by Low Grade
    - 10.1.1.3.4.2 Mexico: North America Glioma Treatment Market, by High Grade
    - 10.1.1.3.5 Mexico: North America Glioma Treatment Market, by End User

11. North America Glioma Treatment Market Industry Landscape

11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
- 11.3.1 Overview
11.4 Inorganic Developments
- 11.4.1 Overview

12. Company Profiles

12.1 F. Hoffmann-La Roche Ltd
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Arbor Pharmaceuticals LLC
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Merck & Co Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Sun Pharmaceutical Industries Ltd
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Amgen Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Teva Pharmaceutical Industries Ltd
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Pfizer Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Amneal Pharmaceuticals Inc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Karyopharm Therapeutics Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Biocon Ltd
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. North America Glioma Treatment Market Segmentation
Table 2. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
Table 3. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
Table 4. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 5. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 6. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 7. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
Table 8. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
Table 9. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
Table 10. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 11. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 12. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 13. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
Table 14. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
Table 15. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
Table 16. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 17. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 18. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 19. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
Table 20. Organic Developments Done By Companies
Table 21. Inorganic Developments Done By Companies
Table 22. Glossary of Terms, North America glioma treatment market

List Of Figures

Figure 1. North America Glioma Treatment Market Segmentation, By Country
Figure 2. North America Glioma Treatment Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030
Figure 5. North America Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
Figure 6. Astrocytoma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Oligodendroglioma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Oligodendroglioma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. North America Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
Figure 10. Surgery: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Chemotherapy: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Radiation Therapy: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
Figure 15. Low Grade: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Grade I: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Grade II: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. High Grade: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Grade III: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Grade IV: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. North America Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
Figure 22. Hospital & Clinics: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Ambulatory Surgical Centers: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. North America Glioma Treatment Market, 2022 ($Mn)
Figure 25. North America Glioma Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 26. US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 27. Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 28. Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 29. Growth Strategies Done by the Companies in the Market, (%)